This week's episode of “The Readout LOUD” is all about health politics, including Marty Makary's departure as FDA ...
The Supreme Court on Thursday preserved women’s access to the abortion drug mifepristone, rejecting lower-court ...
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout ...
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
The surging popularity of alternatives to Alcoholics Anonymous represents a seismic shift in the alcohol treatment landscape.
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...
The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas ...
Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets ...
The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds ...
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates ...
Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval ...
"AI can make great strides in medical decision support, but unfiltered interaction between agent and patient is dangerous," ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results